SCHEMBL2804128

SCHEMBL2804128

COc1cc(C(=O)O)ccc1COc1ccc(C)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC8 Q9BY41 1/20 0.54
KDM4A O75164 1/20 0.53
KDM5A P29375 1/20 0.53
KDM2B Q8NHM5 1/20 0.53
KDM4C Q9H3R0 1/20 0.53
KDM5B Q9UGL1 1/20 0.53
CA12 O43570 1/20 0.51
CA1 P00915 1/20 0.51
CA2 P00918 1/20 0.51
CA4 P22748 1/20 0.51
CA6 P23280 1/20 0.51
CA7 P43166 1/20 0.51
TPMT P51580 1/20 0.51
CA9 Q16790 1/20 0.51
CA14 Q9ULX7 1/20 0.51
RAB9A P51151 2/20 0.51
SMN1; SMN2 Q16637 2/20 0.51
NPC1 O15118 1/20 0.51
POLB P06746 1/20 0.51
TSHR P16473 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2802244 0.88 HDAC8 (0.56) HDAC8RAB9ASMN1; SMN2NPC1TSHR
SCHEMBL16239813 0.83 HDAC8 (0.63) HDAC8KDM5AKDM4CKDM5BCA12
SCHEMBL9516446 0.81 CA12 (0.62) CA12CA1CA2CA4CA6
SCHEMBL9512725 0.79 CA12 (0.61) CA12CA1CA2CA4CA6
SCHEMBL10690676 0.78 L3MBTL1 (0.65) RAB9ASMN1; SMN2NPC1POLBPKM
SCHEMBL31172560 0.78 CA12 (0.51) KDM4AKDM5AKDM2BKDM4CKDM5B
SCHEMBL8890296 0.77 ALDH1A1 (0.61) CA12CA1CA2CA4CA6
SCHEMBL6859656 0.77 CA12 (0.67) CA12CA1CA2CA4CA6
SCHEMBL2592749 0.77 CA12 (0.67) CA12CA1CA2CA4CA6
SCHEMBL2804156 0.76 MRGPRX4 (0.78) CA12CA1CA2CA4CA6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2010132016-A1 BIS-(SULFONYLAMINO) DERIVATIVES FOR TREATMENT OF PAIN AND INFLAMMATION ASTRAZENECA AB (SE) 2010-11-18 WO disclosed
WO-2010132016-A1 BIS-(SULFONYLAMINO) DERIVATIVES FOR TREATMENT OF PAIN AND INFLAMMATION ASTRAZENECA AB (SE) 2010-11-18 WO disclosed
US-20100292279-A1 Bis-(Sulfonylamino) Derivatives in Therapy ASTRAZENECA AB (SE) 2010-11-18 US disclosed
US-20100292279-A1 Bis-(Sulfonylamino) Derivatives in Therapy ASTRAZENECA AB (SE) 2010-11-18 US disclosed
US-20100292279-A1 Bis-(Sulfonylamino) Derivatives in Therapy ASTRAZENECA AB (SE) 2010-11-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100292279-A1 Bis-(Sulfonylamino) Derivatives in Therapy PTGER1, SULT2A1, SULT1E1 HDAC8 3891/4885KDM4A 2072/4885KDM5A 2817/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.